Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Net Margin (2016 - 2025)

Bioadaptives' Net Margin history spans 7 years, with the latest figure at 7896.29% for Q4 2025.

  • On a quarterly basis, Net Margin changed N/A to 7896.29% in Q4 2025 year-over-year; TTM through Dec 2025 was 8860.69%, a 370612.0% decrease, with the full-year FY2025 number at 8523.35%, down 142602.0% from a year prior.
  • Net Margin hit 7896.29% in Q4 2025 for Bioadaptives, up from 8193.05% in the prior quarter.
  • Over the last five years, Net Margin for BDPT hit a ceiling of 265.17% in Q4 2023 and a floor of 27113.63% in Q2 2024.
  • Historically, Net Margin has averaged 5726.46% across 5 years, with a median of 5059.32% in 2022.
  • Biggest five-year swings in Net Margin: plummeted -2248764bps in 2024 and later skyrocketed 2220794bps in 2025.
  • Tracing BDPT's Net Margin over 5 years: stood at 2326.72% in 2021, then tumbled by -200bps to 6990.96% in 2022, then soared by 104bps to 265.17% in 2023, then tumbled by -10325bps to 27113.63% in 2024, then soared by 71bps to 7896.29% in 2025.
  • Business Quant data shows Net Margin for BDPT at 7896.29% in Q4 2025, 8193.05% in Q3 2025, and 4905.68% in Q2 2025.